Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers

2020111 citationsReviewgreen Open Access

Authors

Fausto Petrelli · Azienda Socio Sanitaria Territoriale di Bergamo Ovest

Michele Ghidini · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Gianluca Tomasello · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Abstract

In this meta-analysis of patients with pretreated MSI-H cancer, ICIs were associated with high activity independent of tumor type and drug used. Among molecular biomarkers for selection of treatment, MMR proteins may have a predictive value for the activity of immunotherapy.

Topics & Keywords

Genetic factors in colorectal cancer Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 6, Issue 7, pp. 1068-1068

DOI: 10.1001/jamaoncol.2020.1046

Field-Weighted Citation Impact: 10.30